Trial Profile
A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2017 Status changed from active, no longer recruiting to discontinued because of toxicity and lack of clinical benefit, according to the results published in the Oncologist
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2014 The trial design presented at 50th Annual Meeting of the American Society of Clinical Oncology.